TABLE III.

Efficacy outcomes from the phase iii trial of paclitaxel formulations with carboplatin in the first-line treatment of advanced non-small-cell lung cancer

Outcome		Regimen
Group	Type	(A) Nab-paclitaxel and carboplatin			(B) Paclitaxel a and carboplatin
		(n)	(%)	95% ci	(n)	(%)	95% ci	hr or rrr	95% ci b	p Valuec
Intention-to-treat12		521			531
Median os (months)		12.1		10.8 to 12.9	11.2		10.3 to 12.6	0.922	0.797 to 1.066	ns
Overall response		170	33	28.6 to 36.7	132	25	21.2 to 28.5	1.313	1.082 to 1.593	0.005
	Complete response	0			1	<1
	Partial response	170	33		131	25
	Stable diseased	104	20		128	24
	Progressive disease	83	16		84	16
Squamous subset62		229			221
	Median os (months)	10.7		9.4 to 12.5	9.5		8.6 to 11.6	0.890	0.719 to 1.101	ns
	Overall response	94	41	34.7 to 47.4	54	24	18.8 to 30.1	1.680	1.271 to 2.221	<0.001
Nonsquamous subset62		292			310
	Median os (months)	13.1		nr	13.0		nr	0.950	nr	nr
	Overall response	76	26	21.0 to 31.1	78	25	20.3 to 30.0	1.034	0.788 to 1.358	ns
Age ≥70 subset63		74			82
	Median os (months)	19.9		12.7 to 22.3	10.4		8.6 to 13.6	0.583	0.388 to 0.875	0.009
	Overall response	25	34	23.0 to 44.6	20	24	15.1 to 33.7	1.385	nr	ns
Age <70 subset63		447			449
	Median os (months)	11.4		10.3 to 12.6	11.3		10.3 to 12.9	0.999	0.855 to 1.167	ns
	Overall response	145	32	28.1 to 36.8	112	25	20.9 to 28.9	1.300	NR	0.013

^aSolvent-based.

^bCalculated for rrrs according to the asymptotic 95% ci of the relative risk of regimen A to regimen B.

^cBy chi-square test.

^dDefined as 16 weeks or more.

ci = confidence interval; hr = hazard ratio; rrr = response rate ratio; os = overall survival; ns = nonsignificant; nr = not reported.